The findings reach mice, none yet in people. 2 independent labs in 2 countries; 43 trials, 9 with no results posted.
None of its findings points the other way.
Mice: a single group. Cells, worms or flies and humans: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Includes the processes named after it and trials of drugs aimed at it.
2 independent labs in 2 countries
43 trials, 9 with no results posted
Funders: American Heart Association and 5 more
42 of 43 trials sponsored by developers of drugs aimed at it
Human trial5
Humans4
Animals22
Cells3
In silico2
Interventions
1
Fasting
↑upin mice1
1 study
Fasting activates SLC5A1 in mice.
“fasting resulted in a selective increase in SGLT1 transport activity and Na+ selectivity at tight junctions in the jejunum, but not in the ileum.”
In experiments in mice fed a high-phosphate diet, canagliflozin reduced artery calcification while two related drugs did not.In experiments in mice fed a high-phosphate diet, canagliflozin reduced artery calcification while two related drugs did not.
In a randomized trial of 1,222 patients, benefits did not differ across starting systolic blood pressures of about 90 to 180 mmHg.In a randomized trial of 1,222 patients, benefits did not differ across starting systolic blood pressures of about 90 to 180 mmHg.
Who was studied1,222 people with type 2 diabetes and heart failure
What changedThe reduction in cardiovascular deaths and hospitalizations or urgent visits for heart failure did not differ across starting blood pressure levels
The catchTreatment dose, follow-up duration, and numerical adverse-event rates were not reported